<DOC>
	<DOCNO>NCT00432094</DOCNO>
	<brief_summary>RATIONALE : Germ cell tumor ( GCT ) highly sensitive chemotherapy even metastatic disease diagnosis , many patient cure . Patients fall poor risk category others relapse successfully salvage high dose chemotherapy autologous stem cell transplant ( AuSCT ) . As disease myeloma , sequential high dose chemotherapy AuSCT may improve overall disease free survival . PURPOSE : Because prior investigation GCT suggest subset high risk relapse patient may cure sequential cycle high dose chemotherapy AuSCT , propose investigate well non-cross resistant conditioning regimen work treat patient relapse high risk GCT .</brief_summary>
	<brief_title>Autologous Peripheral Blood Stem Cell Transplant Germ Cell Tumors</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine overall survival ( OS ) patient germ cell tumor treat tandem autologous stem cell transplantation non-cross-resistant conditioning regimen . Secondary - Determine disease-free survival ( DFS ) patient treat regimen . - Determine toxicity tandem transplant - Determine time engraftment neutrophil platelets patient treat transplant - Determine number patient unable adequately mobilize sufficient peripheral blood stem cell ( PBSC ) tandem transplantation . - Identify prognostic factor patient unlikely mobilize sufficient PBSC tandem transplantation . - Compare OS DFS patient undergo single v tandem transplantation . OUTLINE : - Peripheral blood stem cell ( PBSC ) mobilization filgrastim ( G-CSF ) : Patients receive G-CSF subcutaneously ( SC ) begin day 1 continue stem cell collection complete . Patients undergo stem cell collection begin day 5 G-CSF administration continue least 3 collection collection goal meet . - Second PBSC mobilization chemotherapy : Patients meet collection goal receive cyclophosphamide IV 2 hour day 1 G-CSF SC begin day 4 continue stem cell collection complete . Patients meet collection goal PBSC mobilization via G-CSF alone combination chemotherapy undergo tandem autologous transplantation . If collection goal meet patient collect &gt; = 2 x 10^6 CD34 cells/kg , single autologous transplant perform . - Single stem cell transplantation ( SCT ) : Patients receive paclitaxel IV 3 hour day -7 ifosfamide IV day -6 -4 . Patients undergo reinfusion stem cell day 0 . Patients also receive G-CSF SC IV begin day 1 continue blood count recover . - Tandem SCT : Patients receive treatment single SCT . Beginning 30-90 day later , patient receive carboplatin IV 60 minute thiotepa IV 30 minute day -6 -4 etoposide IV 60 minute day -6 -3 . Patients undergo reinfusion stem cell day 0 . Patients also receive G-CSF SC IV begin day 5 continue blood count recover . After completion study treatment , patient follow 6 , 9 , 12 month every 6 month 2 year . PROJECTED ACCRUAL : A total 25 patient accrue study .</detailed_description>
	<mesh_term>Neoplasms , Germ Cell Embryonal</mesh_term>
	<mesh_term>Teratoma</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Thiotepa</mesh_term>
	<mesh_term>Ifosfamide</mesh_term>
	<criteria>Diagnosis : Poor Prognosis NonSeminomas Germ Cell Tumor ≥ PR1/CR1 Good Intermediate Prognosis Seminomas Non Seminomas Germ Cell Tumor ≥ PR1 ≥ CR2 define International Germ Cell Cancer Consensus Classification . Patients increase tumor marker ( i.e . image evidence progressive disease ) eligible transplant . Age : ≥ 10 year &lt; 70 year age . Performance status : Karnofsky ≥ 80 % ( subject ≥ 16 year age ) Lansky ≥ 80 % subject 10 15 year age Life expectancy : Greater 8 week . Patients must normal organ function define : Hematologic : Hemoglobin &gt; 8 gm/dL without transfusion erythropoietin 14 day Aranesp 21 day White blood cell ( WBC ) &gt; 2.5 x 10^9/L absolute neutrophile count ( ANC ) &gt; 1.5 x 10^9/L GCSF GMCSF 10 day Neulasta 21 day Platelets &gt; 100 x 10^9/L without transfusion and/or bone marrow cellularity ≥ 20 % Renal : Creatinine ≤ 2.0 mg/dl creatinine clearance &gt; 50 ml/min . Hepatic : Total bilirubin ≤ 2.0 mg/dl , AST alkaline phosphatase &lt; 5 x upper limit normal . No history severe prior ongoing chronic liver disease . Cardiac : Patients must free symptom uncontrolled cardiac disease include unstable angina , decompensated congestive heart failure , arrhythmia . LVEF ≥45 % MUGA/ECHO . Pulmonary : Patients must significant obstructive airway disease ( FEV1 must ≥ 50 % predict ) must acceptable diffusion capacity ( correct DLCO &gt; 50 % predict ) . Patients history CNS tumor involvement eligible complete treatment CNS disease ( radiotherapy surgery chemotherapy ) , recovered stabilization side effect associate therapy evidence progressive CNS disease time enrollment . Patients serious uncontrolled infection eligible . Male female patient reproductive potential must use approved contraceptive method appropriate ( example , intrauterine device [ IUD ] , birth control pill , barrier device ) duration study participation . The drug use study pregnancy category D clear evidence risk pregnancy . Pregnant breast feed woman eligible . Voluntary write informed consent performance studyrelated procedure part normal medical care , understand consent may withdraw subject time without prejudice future medical care . Additional Eligibility prior Transplant Two : Total Collection ≥ 4 x 10^6 CD34 cells/kg prior transplant one Transplant able occur day +30 day +90 transplant one Recovery blood count demonstrate : WBC &gt; 2.5 x 10^9/L ANC &gt; 1.5 x 10^9/L GCSF 3 day Platelets &gt; 50 x 10^9/L without transfusion prior 7 day Renal : Creatinine ≤ 2.0 mg/dl creatinine clearance &gt; 50 ml/min Hepatic : Total bilirubin ≤ 2.0 mg/dl , AST alkaline phosphatase &lt; 5 x upper limit normal Infection : Patients serious uncontrolled infection time plan transplant exclude Patients progressive disease Response Evaluation Criteria Solid Tumors ( RECIST ) criteria image technique eligible proceed second transplant . Tumor marker increase alone sufficient diagnose disease progression .</criteria>
	<gender>All</gender>
	<minimum_age>10 Years</minimum_age>
	<maximum_age>69 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>childhood extragonadal germ cell tumor</keyword>
	<keyword>childhood malignant ovarian germ cell tumor</keyword>
	<keyword>childhood malignant testicular germ cell tumor</keyword>
	<keyword>stage III malignant testicular germ cell tumor</keyword>
	<keyword>testicular choriocarcinoma seminoma</keyword>
	<keyword>testicular embryonal carcinoma seminoma</keyword>
	<keyword>testicular embryonal carcinoma teratoma seminoma</keyword>
	<keyword>testicular embryonal carcinoma yolk sac tumor seminoma</keyword>
	<keyword>testicular yolk sac tumor teratoma seminoma</keyword>
	<keyword>testicular choriocarcinoma embryonal carcinoma</keyword>
	<keyword>testicular choriocarcinoma teratoma</keyword>
	<keyword>testicular choriocarcinoma yolk sac tumor</keyword>
	<keyword>testicular choriocarcinoma</keyword>
	<keyword>testicular embryonal carcinoma teratoma</keyword>
	<keyword>testicular embryonal carcinoma yolk sac tumor</keyword>
	<keyword>testicular embryonal carcinoma</keyword>
	<keyword>testicular yolk sac tumor teratoma</keyword>
	<keyword>testicular yolk sac tumor</keyword>
	<keyword>testicular seminoma</keyword>
	<keyword>stage IV extragonadal non-seminomatous germ cell tumor</keyword>
	<keyword>stage IV extragonadal seminoma</keyword>
	<keyword>stage I extragonadal non-seminomatous germ cell tumor</keyword>
	<keyword>stage I extragonadal seminoma</keyword>
	<keyword>stage II extragonadal non-seminomatous germ cell tumor</keyword>
	<keyword>stage II extragonadal seminoma</keyword>
	<keyword>stage III extragonadal non-seminomatous germ cell tumor</keyword>
	<keyword>stage III extragonadal seminoma</keyword>
	<keyword>stage II ovarian germ cell tumor</keyword>
	<keyword>stage I malignant testicular germ cell tumor</keyword>
	<keyword>stage II malignant testicular germ cell tumor</keyword>
	<keyword>adult teratoma</keyword>
	<keyword>childhood teratoma</keyword>
	<keyword>testicular immature teratoma</keyword>
	<keyword>testicular mature teratoma</keyword>
	<keyword>adult central nervous system germ cell tumor</keyword>
	<keyword>childhood central nervous system germ cell tumor</keyword>
</DOC>